SCHEMBL12523116

SCHEMBL12523116

Cc1c(-c2ccccc2)nnn1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
KEAP1 Q14145 2/20 0.41
SLC9A1 P19634 1/20 0.41
KMT2A Q03164 4/20 0.40
HSD17B10 Q99714 3/20 0.40
MEN1 O00255 3/20 0.40
POLB P06746 1/20 0.40
MAPK1 P28482 2/20 0.40
CASP1 P29466 1/20 0.40
BRCA1 P38398 1/20 0.40
HTT P42858 1/20 0.40
CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12192020 0.83 ALDH1A1 (0.40) NPC1SMN1; SMN2HSD17B10POLBMAPK1
SCHEMBL25045153 0.80 NPC1 (0.45) NPC1RAB9AALDH1A1DCTPP1
SCHEMBL822713 0.79 KEAP1 (0.45) NPC1RAB9AMAPTSMN1; SMN2KEAP1
SCHEMBL17844431 0.78 NPC1 (0.42) NPC1RAB9AMAPTSMN1; SMN2NR1H2
SCHEMBL25997119 0.78 NPC1 (0.46) NPC1RAB9ADRD2DRD4DRD3
SCHEMBL2687247 0.77 SMN1; SMN2 (0.45) NPC1RAB9ADRD2DRD4DRD3
SCHEMBL23328987 0.77 LMNA (0.40) NPC1RAB9AMAPTSMN1; SMN2POLB
SCHEMBL19707872 0.77 P2RX3 (0.40) NPC1RAB9AMAPTHTTTSHR
SCHEMBL13325667 0.76 NPC1 (0.62) NPC1RAB9AMAPTSMN1; SMN2KMT2A
SCHEMBL13325677 0.75 NPC1 (0.44) NPC1RAB9ADRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed
US-8362004-B2 Piperazine analogs as broad-spectrum influenza antivirals BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120238539-A1 NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238539-A1 NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS ZC3HAV1, ZC3HAV1L, HCRTR1 NPC1 912/4885RAB9A 2247/4885DRD2 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.